Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Hepatitis B is a viral infection caused due to transmission of the virus through contact with the blood or other body fluids of an infected person. It is considered as a serious occupational hazard for healthcare professionals, which affects the liver, causing acute and chronic diseases. Hence, Chinese hamster ovary cell (CHO) hepatitis B vaccine is considered to be the safe and effective method to prevent the hepatitis B infection. The major factor that fuels the growth of the market are increase in prevalence of hepatitis B infection worldwide. For example, approximately 887,000 deaths due to hepatitis B infection were recorded in 2015 across the globe. However, inherent disadvantages of using recombinant Chinese hamster ovary cell (CHO) to design hepatitis B vaccines restrains the growth of the market. Conversely, increase in government focus to promote (CHO) hepatitis B vaccination for adults and extensive research carried out for the same are expected to offer lucrative opportunities for the market.
Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospitals and Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine key manufacturers include Merck & Co., Inc., GlaxoSmithKline Plc, Pfizer Inc., Sanofi Pasteur, CSL Limited, Emergent Biosolutions, Serum Institute of India and Johnson & Johnson, etc. Merck & Co., Inc., GlaxoSmithKline Plc, Pfizer Inc. are top 3 players and held % sales share in total in 2022.
Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine can be divided into Pediatric Hepatitis B (CHO) Vaccine and Adult Hepatitis B (CHO) Vaccine, etc. Pediatric Hepatitis B (CHO) Vaccine is the mainstream product in the market, accounting for % sales share globally in 2022.
Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine is widely used in various fields, such as Hospitals and Clinics, etc. Hospitals provides greatest supports to the Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine industry development. In 2022, global % sales of Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine went into Hospitals filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Merck & Co., Inc.
GlaxoSmithKline Plc
Pfizer Inc.
Sanofi Pasteur
CSL Limited
Emergent Biosolutions
Serum Institute of India
Johnson & Johnson
Segment by Type
Pediatric Hepatitis B (CHO) Vaccine
Adult Hepatitis B (CHO) Vaccine
Hospitals
Clinics
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine introduction, etc. Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospitals and Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine key manufacturers include Merck & Co., Inc., GlaxoSmithKline Plc, Pfizer Inc., Sanofi Pasteur, CSL Limited, Emergent Biosolutions, Serum Institute of India and Johnson & Johnson, etc. Merck & Co., Inc., GlaxoSmithKline Plc, Pfizer Inc. are top 3 players and held % sales share in total in 2022.
Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine can be divided into Pediatric Hepatitis B (CHO) Vaccine and Adult Hepatitis B (CHO) Vaccine, etc. Pediatric Hepatitis B (CHO) Vaccine is the mainstream product in the market, accounting for % sales share globally in 2022.
Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine is widely used in various fields, such as Hospitals and Clinics, etc. Hospitals provides greatest supports to the Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine industry development. In 2022, global % sales of Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine went into Hospitals filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Merck & Co., Inc.
GlaxoSmithKline Plc
Pfizer Inc.
Sanofi Pasteur
CSL Limited
Emergent Biosolutions
Serum Institute of India
Johnson & Johnson
Segment by Type
Pediatric Hepatitis B (CHO) Vaccine
Adult Hepatitis B (CHO) Vaccine
Segment by Application
Hospitals
Clinics
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine introduction, etc. Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices